Characterization of fluoroquinolone resistance among veterinary isolates of avian Escherichia coli.
Fluoroquinolone-resistant avian Escherichia coli isolates from northern Georgia were investigated for gyrA and parC mutations. All isolates contained a mutation in GyrA replacing Ser83 with Leu; seven isolates also contained mutations replacing Asp87 with either Gly or Tyr. Random amplified polymorphic DNA analysis revealed that quinolone-resistant E. coli isolates were genetically diverse.
White
D G
DG
Department of Veterinary and Microbiological Sciences, North Dakota State University, Fargo, North Dakota, USA. dwhite@cvm.fda.gov
Piddock
L J
LJ
Maurer
J J
JJ
Zhao
S
S
Ricci
V
V
Thayer
S G
SG
D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology*; D027081:DNA Gyrase; D027101:DNA Topoisomerase IV; D004250:DNA Topoisomerases, Type II / Q000235:genetics; D004269:DNA, Bacterial / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects* / Q000235:genetics; D004927:Escherichia coli Infections / Q000453:epidemiology / Q000382:microbiology* / Q000662:veterinary*; D024841:Fluoroquinolones; D005845:Georgia / Q000453:epidemiology; D009268:Nalidixic Acid / Q000494:pharmacology; D012150:Polymorphism, Restriction Fragment Length; D011200:Poultry / Q000382:microbiology*; D011201:Poultry Diseases / Q000382:microbiology*; D020133:Reverse Transcriptase Polymerase Chain Reaction
D000890:Anti-Infective Agents; D004269:DNA, Bacterial; D024841:Fluoroquinolones; D009268:Nalidixic Acid; D027101:DNA Topoisomerase IV; D027081:DNA Gyrase; D004250:DNA Topoisomerases, Type II